Etern Biopharma

Focus: Etern Biopharma is a Shanghai-based oncology-focused biotech company specializing in condensate targeting and undruggable protein therapeutics, a nascent and innovative modality space.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Etern Biopharma

AI assessmentNot Hiring

No open roles listed right now. Follow Etern Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ET0111

Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT05522309FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid Tumors

Phase 1

Help build intelligence for Etern Biopharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge condensate targeting technology platform, a differentiated approach to previously intractable oncology targets
Early-stage opportunity to shape drug discovery and development strategy in an emerging modality with significant unmet need in solid tumors
Positioned in Shanghai with access to Asian oncology markets and potential partnerships with local and global pharma players

Watch Out For

No active job openings currently available, suggesting either minimal expansion or hiring pause
Only Phase 1 programs in pipeline with no clinical catalysts on horizon; earliest data likely years away
Minimal public information on funding, financials, or employee headcount raises transparency and sustainability questions

Generated by Claude from Etern Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ET0038

Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT05525559SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors

Phase 1

ET0038

Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT05354843SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors

Phase 1

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

3 pipeline

Marketed

Pipeline